Search Results
Keyword:cancer
Cancer Cryoablation Treatments at Southeast Region Nuclear Medicine Center in Korea Exceed 100 Cases
The Southeast Region Nuclear Medicine Center announced on August 8 that since introducing cancer cryoablation in 2024, the center has completed over 100 related procedures, providing treatment to a total of 104 cancer patients. Cryoablation is a minimally invasive tumor treatment method. During the procedure, doctors insert a thin treatment needle precisely into the tumor site under CT or ultrasound imaging guidance, freezing the lesion at ultra-low temperatures of minus 40 degrees Celsius or lower to cause cancer cell necrosis. As the low-temperature freezing itself has a certain anesthetic effect, this technique helps reduce patient pain, minimize damage to surrounding normal tissues, and promote faster postoperative recovery. According to the center, among the patients treated so far, there are 58 cases of liver cancer and liver metastases, 17 cases of primary lung cancer, recurrent lung cancer, and lung metastases, and 29 cases of renal cancer. Among them, 8 patients underwent treatment for two lesions simultaneously in a single procedure. Liver...
2026-08-08
Professor Lin Guoxian from the BC Cancer Agency Delivers Academic Exchange at the Institute of Radiation Medicine, Chinese Academy of Medical Sciences
Lin Guoxian: Professor at the BC Cancer Agency, whose research focuses on the development of targeted radiopharmaceuticals for the diagnosis and treatment of various tumors. To date, he has led/participated in the publication of over 135 peer-reviewed journal articles, filed more than 30 patent applications related to radiopharmaceuticals, and completed the clinical translation of 7 self-developed radiopharmaceuticals for the diagnosis and treatment of multiple tumor types. During the seminar, Professor Lin Guoxian, based on his team's years of frontier exploration, systematically reviewed the research progress of nuclear drugs targeting PSMA for prostate cancer: first, the molecular design and clinical advantages of F-18 labeled PSMA-targeted PET imaging agents; second, the substantial improvement of tumor targeting of Lu-177 labeled therapeutic radiopharmaceuticals through rational optimization of molecular structures,...
2026-08-07
South Korea Advances First Domestic Commercial Production of Lu-177 Using Wolsong Heavy Water Reactors
Korea Hydro & Nuclear Power (KHNP) plans to use the heavy water reactors at the Wolsong Nuclear Power Plant to produce, for the first time domestically, the radioisotope lutetium-177 (Lu-177) for cancer treatment. Currently, South Korea relies entirely on imports for this material, which imposes cost pressures and supply instability on local radiopharmaceutical companies such as Cellbion and FutureChem. Industry experts generally believe that domestic production will help build a diversified supply chain and shorten transportation times. The primary goal of this plan is to achieve commercial production of Lu-177, with pilot production expected in 2028 and full-scale production commencing in 2031. Subsequently, KHNP will expand production to include cobalt...
2026-08-06
Bahamas to Strengthen Cancer Control System Based on imPACT Review Findings
August 5, 2026, an international review led by the International Atomic Energy Agency showed that the Bahamas has room for further improvement in strengthening cancer treatment services. The review provided a roadmap for the country to improve coordination of cancer services, reduce diagnostic and treatment waiting times, and enhance patient outcomes. Princess Margaret Hospital in Nassau, Bahamas (Image: Pelow Media/Adobe Stock) The imPACT review was conducted jointly by the International Atomic Energy Agency, the World Health Organization/Pan American Health Organization, and the International Agency for Research on Cancer, at the request of the Bahamas Ministry of Health and Wellness, focusing on assessing the country's cancer control capacities and needs. From June 9 to 11, the expert team visited...
2026-08-06
CNNC & CIR Co-sponsors Regional Nuclear Medicine Department Development Training Program (Ganzhou Session) and Ganzhou Cancer Hospital High-Quality Nuclear Medicine Diagnosis and Treatment Project Launched Simultaneously
Recently, the Regional Nuclear Medicine Department Development Training Program (Ganzhou Session) and the Ganzhou Cancer Hospital High-Quality Nuclear Medicine Diagnosis and Treatment Project were launched simultaneously at Ganzhou Cancer Hospital. An expert panel from the Nuclear Medicine Branch of the Chinese Medical Association, along with representatives from CNNC & CIR and Atom High-Tech, visited the hospital for research and exchange. More than 200 medical staff from medical institutions at various levels across Jiangxi Province attended the event. The launch ceremony was moderated by Yang Chuansheng, Director of the Nuclear Medicine Department at Ganzhou Cancer Hospital. Fu Wei, Deputy Director of the Ganzhou Municipal Health Commission; Wang Jing, Chair of the Nuclear Medicine Branch of the Chinese Medical Association; and Huang Xingwei, Party Secretary of Ganzhou Cancer Hospital, attended and delivered speeches. Wang Jing stated that nuclear medicine plays a vital supporting role in the precise diagnosis and treatment of major diseases such as cancer, and that promoting the standardized development of regional nuclear medicine at the city and county levels is conducive to channeling high-quality medical resources to the grassroots and enhancing primary healthcare service capabilities.
2026-08-06
UT-ORNL Recruits Radiopharmaceutical Scientist to Advance Integrated Cancer Diagnosis and Treatment
The University of Tennessee and Oak Ridge National Laboratory jointly announced that Dr. Carolyn Anderson has been appointed to the UT-ORNL Governor's Chair in Nuclear Medicine: Radiopharmaceutical Therapy. Anderson officially assumed the position on August 1, serving concurrently as a professor in the Department of Nuclear Engineering at the University of Tennessee, Knoxville, and as a researcher in the Isotope Science and Enrichment Directorate at Oak Ridge National Laboratory. She is an internationally renowned pioneer in the field of radiopharmaceutical science, having worked at institutions such as the University of Washington, the University of Pittsburgh, and the University of Missouri. Dr. Anderson's research focuses on developing compounds that can identify cancer earlier, assess treatment efficacy, and deliver radiation directly to tumors...
2026-08-04
DuChemBio Completes Supply Chain for Prostate Cancer Radiopharmaceutical
DuChemBio, a Korean radiopharmaceutical company, announced on August 4 that it has completed the supply chain for ProstaSeek (active ingredient: 18F-plotupolastat), a radiopharmaceutical for prostate cancer diagnosis, in the Yeongnam and Honam regions. The drug targets prostate-specific membrane antigen (PSMA), and all tertiary general hospitals in both regions that perform PET-CT scans and provide prostate cancer diagnosis and treatment have been included in its supply scope. According to data from the National Cancer Registry of the Korean Ministry of Health and Welfare, new prostate cancer cases reached 22,640 in 2023, accounting for 7.8% of all cancer cases and ranking sixth in male cancer incidence; with the increasing adoption of PSMA-targeted therapy, the demand for precise diagnosis before prostate cancer treatment is also growing rapidly.
2026-08-04
US FDA Approves Pluvicto Expanded Indication for Treatment of PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer
On July 31, 2026, Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor (ARPI) for the treatment of patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naive/sensitive prostate cancer. This disease is commonly referred to as metastatic hormone-sensitive prostate cancer (mHSPC). The approval is based on results from the Phase III PSMAddition trial. The study showed that compared with standard of care alone, namely ARPI combined with androgen deprivation therapy (ADT), Pluvicto plus standard of care reduced the risk of disease progression or death by...
2026-08-03
Santa Casa Hospital in Ceará, Brazil, Introduces New Linear Accelerator for Cancer Treatment
Santa Casa de Sobral Hospital in northern Ceará, Brazil, has introduced a new linear accelerator to strengthen cancer treatment for patients in the northern region. The hospital received a new linear accelerator for radiotherapy of cancer patients. After completing the installation, training, and licensing processes, this new technology is expected to double the institution's radiotherapy capacity, increasing from the current 600 patients per month to approximately 1,200 new patients. This equipment, the Halcyon linear accelerator, is considered the latest technology in radiotherapy and is the second unit of its kind installed in Ceará. The device is capable of providing faster, more precise, and safer treatment for various types of cancer...
2026-08-01
Kangbuk Samsung Hospital in South Korea Validates Precision of New-Generation Surface-Guided Radiation Therapy System
The research team from the Department of Radiation Oncology at Kangbuk Samsung Hospital in South Korea announced on July 31 that they have completed validation of the geometric accuracy and respiratory tracking performance of a new-generation surface-guided radiation therapy system. The research findings have been published in the latest issue of the international academic journal *Radiation Physics and Chemistry*. In breast cancer radiotherapy, the deep inspiration breath-hold technique is commonly used in clinical practice to reduce radiation exposure to the heart and lungs. Traditional procedures typically require tattoo marks or drawn guide lines on the patient's skin surface, along with wearing sensors to monitor respiratory motion, which somewhat compromises treatment convenience and patient comfort. The new-generation surface-guided radiation therapy system validated in this study utilizes 3D stereoscopic cameras and thermal imaging technology...
2026-08-02
Russian State Expert Review Authority Approves Design Changes for Ufa Radionuclide Therapy Center
Russia approves design changes for the Ufa Radionuclide Therapy Center, which will employ the latest technologies and equipment. The new center, located in the Republic of Bashkortostan, is expected to become a significant force in the local fight against cancer. With a floor area exceeding 6,000 square meters, the facility is a G-shaped three-story building with a basement. Its internal framework uses monolithic reinforced concrete to ensure stability and safety. The project's design strictly adheres to medical technology standards, aiming to create a modern and innovative treatment institution. At the core of the center is the radionuclide therapy department, which includes 24-hour inpatient wards, featuring a radionuclide supply area, a 20-bed "active" ward, and common areas. Additionally, it includes service and administrative zones to support the center's daily operations...
2026-08-01
TerraPower Isotopes to Donate Actinium-225 via Oncidium Foundation to Support Cancer Treatment Accessibility
TerraPower Isotopes (TPI), a subsidiary of U.S. nuclear innovation company TerraPower, announced on July 29 that it will coordinate the donation of the rare medical isotope actinium-225 (Ac-225) through the Oncidium Foundation to support economically disadvantaged cancer patients in accessing targeted radionuclide therapy. The Oncidium Foundation is a non-profit organization dedicated to promoting global access to targeted radionuclide cancer treatments. Its RLT-Connect program aims to help financially challenged patients access relevant therapies, reducing treatment disparities caused by geographic and economic conditions. This donation also marks TPI's entry into Oncidium's collaborative ecosystem of radioisotope suppliers, medical practitioners...
2026-07-30
Moffitt Cancer Center Activates Proton Therapy Center in Florida, USA
Moffitt Cancer Center recently held a ribbon-cutting ceremony, announcing the official opening of the Richard M. Schultz Family Foundation Proton Center at the Moffitt Speros Outpatient Center. Located in the Speros Global R&D Park in Pasco County, Florida, it is recognized as the first proton therapy center in the Tampa Bay area. Moffitt Cancer Center stated that the activation of the proton therapy center will provide local patients with more precise radiotherapy options. Built in collaboration with IBA, a particle accelerator technology company, the center will use proton therapy to deliver targeted radiation to tumors, improving tumor targeting accuracy while minimizing impact on surrounding healthy tissues. According to reports, the...
2026-07-30